Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoblastic Leukemia, Acute, Childhood
Open-data reference.
5 US clinical trials ·
Active & Recent Trials
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
NCT03817320
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
University of Pennsylvania
NCT02906371
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
National Cancer Institute (NCI)
NCT05440409
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
NCT01861002
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Genzyme, a Sanofi Company
NCT00991133
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 4 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Lymphoblastic Leukemia, Acute, Childhood Trial Landscape
ClinicalTrials.gov lists 5 US studies indexed under Lymphoblastic Leukemia, Acute, Childhood, and 0 of those are currently open to recruitment — roughly 0% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Lymphoblastic Leukemia, Acute, Childhood shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 4 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Lymphoblastic Leukemia, Acute, Childhood is led by Therapeutic Advances in Childhood Leukemia Consortium with 2 indexed trials, alongside 3 other organizations in the top contributor list. The list on this page surfaces up to 5 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Lymphoblastic Leukemia, Acute, Childhood?
PlainTrial tracks 5 US clinical trials for Lymphoblastic Leukemia, Acute, Childhood, of which 0 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Lymphoblastic Leukemia, Acute, Childhood?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.